BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 30093157)

  • 1. Transforming growth factor-beta 1 polymorphisms and anti-tuberculosis drug-induced liver injury. Polymorphisms in TGFβ1 and its relationship with anti-tuberculosis drug-induced liver injury.
    Wu S; Wang Y; Zhang M; Wang M; He JQ
    Therapie; 2019 Jun; 74(3):399-406. PubMed ID: 30093157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han.
    Chen G; Wu SQ; Feng M; Wang Y; Wu JC; Ji GY; Zhang MM; Liu QQ; He JQ
    Int J Immunopathol Pharmacol; 2017 Dec; 30(4):434-438. PubMed ID: 28934901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of LEPR polymorphisms with predisposition and inflammatory response in anti-tuberculosis drug-induced liver injury: A pilot prospective investigation in Western Chinese Han population.
    Zhao Z; Peng W; Zhou J; Zhou Y; Liu T; Bai H; Wu Q; Song J; Wu L; Song X; Ying B
    Infect Genet Evol; 2019 Nov; 75():103970. PubMed ID: 31325611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible association of HMOX1 and NQO1 polymorphisms with anti-tuberculosis drug-induced liver injury: A matched case-control study.
    Yang M; Zhang H; Tao B; Pan H; Lu L; Yi H; Tang S
    J Clin Pharm Ther; 2019 Aug; 44(4):534-542. PubMed ID: 30776144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of NAT2 polymorphism and methylation in anti-tuberculosis drug-induced liver injury in Mongolian tuberculosis patients.
    Zhang D; Hao J; Hou R; Yu Y; Hu B; Wei L
    J Clin Pharm Ther; 2020 Jun; 45(3):561-569. PubMed ID: 32364660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population.
    Tang SW; Lv XZ; Chen R; Wu SS; Yang ZR; Chen DF; Zhan SY
    Clin Exp Pharmacol Physiol; 2013 May; 40(5):326-32. PubMed ID: 23469989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study.
    Chen R; Zhang Y; Tang S; Lv X; Wu S; Sun F; Xia Y; Zhan SY
    J Clin Pharm Ther; 2015 Feb; 40(1):110-5. PubMed ID: 25250564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between genetic polymorphisms of NRF2, KEAP1, MAFF, MAFK and anti-tuberculosis drug-induced liver injury: a nested case-control study.
    Chen S; Pan H; Chen Y; Lu L; He X; Chen H; Chen R; Zhan S; Tang S
    Sci Rep; 2019 Oct; 9(1):14311. PubMed ID: 31586142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of significant association between UGT2B4 genetic variants and the susceptibility to anti-tuberculosis drug-induced liver injury in a Western Chinese population.
    Chen H; Jiao L; Zhou J; Bai H; Lyu M; Wu T; Wu L; Song J; Liu T; Yan H; Ying B
    J Clin Pharm Ther; 2021 Feb; 46(1):66-73. PubMed ID: 32170986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.
    Shang P; Xia Y; Liu F; Wang X; Yuan Y; Hu D; Tu D; Chen Y; Deng P; Cheng S; Zhou L; Ma Y; Zhu L; Gao W; Wang H; Chen D; Yang L; He P; Wu S; Tang S; Lv X; Shu Z; Zhang Y; Yang Z; Chen Y; Li N; Sun F; Li X; He Y; Garner P; Zhan S
    PLoS One; 2011; 6(7):e21836. PubMed ID: 21750735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity.
    Wu S; Wang YJ; Tang X; Wang Y; Wu J; Ji G; Zhang M; Chen G; Liu Q; Sandford AJ; He JQ
    PLoS One; 2016; 11(6):e0157478. PubMed ID: 27281183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.
    Xiang Y; Ma L; Wu W; Liu W; Li Y; Zhu X; Wang Q; Ma J; Cao M; Wang Q; Yao X; Yang L; Wubuli A; Merle C; Milligan P; Mao Y; Gu J; Xin X
    PLoS One; 2014; 9(1):e85905. PubMed ID: 24465778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
    Wang PY; Xie SY; Hao Q; Zhang C; Jiang BF
    Int J Tuberc Lung Dis; 2012 May; 16(5):589-95. PubMed ID: 22409928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of ABO blood group and antituberculosis drug-induced liver injury: A case-control study from a Chinese Han population.
    Tao B; Yang M; Chen H; Pan H; Liu W; Yi H; Tang S
    J Clin Pharm Ther; 2020 Aug; 45(4):638-645. PubMed ID: 32259340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on polymorphisms of genes with susceptibility to drug induced liver injury in a cohort receiving anti-tuberculosis treatment].
    Chen R; Wang J; Tang SW; Lyu XZ; Zhang Y; Wu SS; Xia YY; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Jul; 37(7):925-9. PubMed ID: 27453098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are genetic variations in glutathione S-transferases involved in anti-tuberculosis drug-induced liver injury? A meta-analysis.
    Zhang M; Wu SQ; He JQ
    J Clin Pharm Ther; 2019 Dec; 44(6):844-857. PubMed ID: 31378997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis.
    Sun F; Chen Y; Xiang Y; Zhan S
    Int J Tuberc Lung Dis; 2008 Sep; 12(9):994-1002. PubMed ID: 18713495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of silent information regulator 1 (SIRT1) gene polymorphisms in antituberculosis- drug-induced hepatotoxicity in a prospective cohort study.
    Wang Y; Yan XY; Wu JC; Ji GY; Wu SQ; Huang WW; Chen G; Sandford AJ; He JQ
    Int J Clin Pharmacol Ther; 2016 Oct; 54(10):775-81. PubMed ID: 26952036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antituberculosis Drug-induced Liver Injury in Children: Incidence and Risk Factors During the Two-month Intensive Phase of Therapy.
    Gafar F; Arifin H; Jurnalis YD; Yani FF; Fitria N; Alffenaar JC; Wilffert B
    Pediatr Infect Dis J; 2019 Jan; 38(1):50-53. PubMed ID: 30234790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of POR and PPARα polymorphisms with risk of anti-tuberculosis drug-induced liver injury in Western Chinese Han population.
    Zhang C; Jiao L; Bai H; Zhao Z; Hu X; Wang M; Wu T; Peng W; Liu T; Song J; Zhou J; Li M; Lyv M; Zhang J; Chen H; Chen J; Ying B
    Infect Genet Evol; 2020 Apr; 79():104147. PubMed ID: 31857256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.